SSG
SNDX icon

Summit Securities Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Summit Securities Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-688
Closed -$10.6K – 1234
2025
Q3 		$10.6K Buy
+688
New +$9.01K ﹤0.01% 870

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Summit Securities Group's SNDX Position: Q4 2025 in Review

Summit Securities Group sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 688 shares — an estimated $10.6K sold.

Summit Securities Group first reported a position in SNDX in Q3 2025 and held it in 1 quarter. The position peaked at $10.6K in Q3 2025. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

  • Summit Securities Group reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Summit Securities Group sold 688 Syndax Pharmaceuticals shares in Q4 2025, an estimated $10.6K.
  • Summit Securities Group first reported a position in Syndax Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Summit Securities Group's Syndax Pharmaceuticals position peaked at $10.6K in Q3 2025.
  • 229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.